CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions		3 Months Ended
		Apr. 04, 2021	Mar. 29, 2020
Income Statement [Abstract]
Revenues	[1]	$ 14,582	$ 10,083
Costs and expenses:
Cost of sales	[2]	4,211	1,940
Selling, informational and administrative expenses	[2]	2,783	2,541
Research and development expenses	[2]	2,014	1,672
Amortization of intangible assets		872	849
Restructuring charges and certain acquisition-related costs		23	54
(Gain) on completion of Consumer Healthcare JV transaction		0	(6)
Other (income)/deductions––net		(1,004)	190
Income from continuing operations before provision for taxes on income		5,683	2,842
Provision for taxes on income		805	359
Income from continuing operations		4,877	2,483
Income from discontinued operations––net of tax		9	881
Net income before allocation to noncontrolling interests		4,886	3,364
Less: Net income attributable to noncontrolling interests		9	9
Net income attributable to Pfizer Inc. common shareholders		$ 4,877	$ 3,355
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 0.87	$ 0.45
Income from discontinued operations––net of tax (in dollars per share)		0	0.16
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		0.87	0.60
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)		0.86	0.44
Income from discontinued operations––net of tax (in dollars per share)		0	0.16
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)		$ 0.86	$ 0.60
Weighted-average shares––basic		5,584	5,545
Weighted-average shares––diluted		5,662	5,613

[1] On November 16, 2020, we completed the spin-off and the combination of our Upjohn Business with Mylan to form Viatris. See Note 1A. Beginning in the fourth quarter of 2020, the results of our Meridian subsidiary, which was previously included in our former Upjohn operating segment, are reported in the Hospital therapeutic area for all periods presented.

[2] Exclusive of amortization of intangible assets, except as disclosed in Note 9 in this Form 10-Q and Note 1L in our 2020 Form 10-K.